Story perspectives

Isomorphic Labs Seeks $2 B+, Thrive Leads, Alphabet Invests

5/9/2026

Summary

Isomorphic Labs Funding

Isomorphic Labs is in advanced talks to raise more than $2 billion in new funding.
Thrive Capital will lead the round.
Alphabet also intends to invest in the financing.
The capital will fund the drug-design engine and support global expansion.
In March 2025, it raised $600 million in a round led by Thrive Capital with Alphabet and GV, which could bring nearly $3 billion in milestone payments.

Summary

Isomorphic Labs Funding

AI funding is shifting from generic tools to drug discovery and manufacturing.
Investors now evaluate AI-biotech firms on clinical-approval odds instead of SaaS revenue growth.
Google’s capital lets Isomorphic pursue decade-long drug programs that most venture-backed startups cannot afford.
Experts say biology outpaces AI, requiring proprietary data, tight lab-software loops, massive compute and deep capital, which creates a winner-take-most market.

History

Historical Context

DeepMind’s AlphaFold2 won CASP14 in November 2020, scoring a median 92.4 GDT, a level comparable to experimental methods. Built on deep-learning and released through a free database with EMBL-EBI, the result spurred massive AI-health investment, culminating in a 2024 Nobel Prize for Demis Hassabis and John Jumper and reshaping biotech venture strategies.

1 of 3

Isomorphic Labs Funding

Isomorphic Labs is in advanced talks to raise more than $2 billion in new funding.
Thrive Capital will lead the round.
Alphabet also intends to invest in the financing.
The capital will fund the drug-design engine and support global expansion.
In March 2025, it raised $600 million in a round led by Thrive Capital with Alphabet and GV, which could bring nearly $3 billion in milestone payments.

1 / 3